A Chinese pharmaceutical company, which focuses on R&D, production, sales and service of liposome drugs, is looking for a R&D institute or technology developer in Finland to co-develop a liposome product of antitumor drugs.
Established in 1993, this Chinese enterprise has a mature liposome technology platform, focusing on the R & D, production, sales and service of liposome drugs. With a construction area of 20,000 square meters, this company has its own Good Manufacturing Practice-compliant comprehensive preparation workshops, anti-tumor drug workshops, laboratory buildings, central laboratory, comprehensive office buildings and other ancillary facilities. Besides, it has already introduced advanced production equipment and physical and chemical analysis instruments at home and abroad. Since it wants to improve its products and expand market share in China, it would like to find a technological partner in Finland in jointly developing a liposome product of antitumor drugs. The partner should have a mature grasp of the liposome core technology, rich experience of R & D team, and related R & D equipment. During the cooperation, the partner is expected to provide technical support in solving problems of prescription and technology that affect product quality and improving the liposome technology in cancer treatment.
- Type of partner sought: R&D capacity in liposome core technology as targeting drug system in cancer treatment
- Specific area of activity of the partner: R&D institute, co-developer, technology provider,etc.
02/04/2019 - UK Funding for Innovation
04/06/2019 - Future of Building 2019